NOUSCOM, an oncology company developing neoantigen based cancer vaccines, announced the completion of a EUR 42m Series B financing. The round involved a syndicate of leading transatlantic life sciences investors led by new investors Abingworth with participation from 5AM Ventures and the existing investors LSP and Versant Ventures.
VISCHER acted as counsel to NOUSCOM. The team was led by Dr. Matthias Staehelin (Partner) and supported by Luzius Zumstein (Associate), both Corporate.